A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Estimate The Effect Of Age On The Pharmacokinetics, Safety And Tolerability Of Intravenous Rivipansel (Pf-06460031)
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Rivipansel (Primary)
- Indications Haematological malignancies; Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 06 Apr 2017 Status changed from recruiting to completed.
- 13 Mar 2017 Planned End Date changed from 1 Apr 2017 to 16 Mar 2017.